Floatz logo

ly03010

Central Nervous System Depressants

Luye Pharma Group Ltd.Phase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Central Nervous System Depressants cohort.

Asset / SponsorPhaseRating
Vts-K
Theresa Jacob, PhD, MPH
Phase 4BB
Paliperidone Palmitate 3-Month Formulation
Luye Pharma Group Ltd.
Phase 1CC
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Aretaieion University Hospital
N/AD
FENTANYL
Aretaieion University Hospital
N/AD
Bxcl501
Aretaieion University Hospital
N/AD
LIDOCAINE
Aretaieion University Hospital
N/AD

Same molecule, other indications

ly03010 is also rated in:

Antipsychotic AgentsDormant
CCC
Indicative ·
52 / 100
View asset →
mood disorderDormant
CCC
Indicative ·
52 / 100
View asset →
Physiological Effects of DrugsDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →